Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model

Experimental and Molecular Medicine

Volumn 40, Issue 5, 2008, Pages 574-581

  Choi, Yongseok ^a   Park, Song Kyu ^b   Hwan, Mook Kim ^b   Jong, Soon Kang ^b   Yeo, Dae Yoon ^b   Sang, Bae Han ^c   Jeung, Whan Han ^d   Jee, Sun Yang ^e   Han, Gyoonhee ^e  

^a Korea University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Chungbuk National University   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Yonsei University   (South Korea)

Author keywords

Anti inflammatory agents; Histone deacetylases; NF B; Nitric oxide; Transcription factor AP 1; Tumor necrosis factor ; Vorinostat

Indexed keywords

DNA; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; KBH A42; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; DOSE RESPONSE; DRUG EFFECT; DRUG PROTEIN BINDING; ENDOTOXEMIA; ENZYME PHOSPHORYLATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN BLOOD LEVEL; PROTEIN DNA BINDING; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 57349114027     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2008.40.5.574     Document Type: Article

References (23)

1. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of colon cancer cells. Proc Natl Acad Sci USA 1998;95:6791-6
2. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999;9:171-4
3. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drug for the treatment of inflammatory diseases? Drug Discovery Today 2005;3:197-204
4. Chakravortty D, Koide N, Kato Y, Sugiyama T, Mu MM, Yoshida T, Yokochi T. The inhibitory action of butyrate on lipopolysccharide induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000;6:243-7
5. D'Acuisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa (NF-κB): an emerging theme in anti-inflammatory therapies. Mol Interv 2002;2:22-35
6. Diakos C, Prieschl EE, Saemann M, Novotny V, Bohmig G, Csonga R, Baumruker T, Zlabinger GJ. Novel mode of interference with nuclear factor of activated T-cells regulation in T-cell by bacterial metabolite n-butyrate. J Biol Chem 2002;277:24243-51
7. Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Najar VCO. A New Simple and High-Yield Synthesis of Suberoylanilide Hydroxamic Acid and Its Inhibitory Effect Alone or Combination with Retinoids on Proliferation of Human Prostate Cancer Cells. J Med Chem 2005;48:5047-51
8. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245-54
9. Johnstone RW. Histone decetylase inhibitors: Novel drugs for the treatment of cancer. Nature Rev Drug Discovery 2002;1:287-99
10. Kim HM, Lee K, Park BW, Ryu DK, Kim K, Lee CW, Park S-K. Han JW, Lee HY, Han G. Synthesis, Enzymatic Inhibition and Cancer Cell Growth Inhibition of Novel δ-Lactam-Based Histone Deacetylase (HDAC) Inhibitors. Bioorg Med Chem Lett 2006;16:4068-70
11. Kim HM, Ryu DK, Choi Y. Park BW, Lee K, Han SB, Lee CW, Kang MR, Kang JS, Boovanahalli SK, Park SK, Han JW, Chun TG, Lee HY, Nam KY, Choi EH, Han G. Structure-Activity Relationship Studies of a Series of Novel δ-Lactam based Histone Deacetylase Inhibitors J Med Chem 2007;50:2737-41
12. Kouzarides T. Histone acetylase and deacetylase in cell proliferation. Curr Opin Genet Dev 1999;9:40-8
13. Kyung TW, Lee JE, Shin HH, Choi HS. Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-α by inhibiting activation of NF-κB. Exp Mol Med 2008;40:52-8
14. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim S-H, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002;99:2995-3000
15. Lipsky PE, van der Heijde DM, St. Clair W, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
16. McMartin C, Bohacek RS. QXP: Powerful, rapid computer algorithms for structure-based drug design. J Comput Aided Mol Des 1997;11:333-44
17. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7
18. Newton RC, Decicco CP. Therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J Med Chem 1999;42:2295-314
19. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-α therapies: the next generation. Nature Rev Drug Discovery 2003;2:736-46
20. Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stockl J, Walter H, Horl WH, Zlabinger GJ. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 2000;14:2380-2
21. Wu J, Grunstein M. 25 years after the nucleosome model: chromatin modifications. Trends Biochem Sci 2000;25:619-3
22. WAF1 contributes to osteoclast apoptosis. Exp Mol Med 2007;39:213-21
23. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-κB activation and cellular proteosome activation. J Biol Chem 2001;276:44641-6